XTANDI® is the first and only androgen receptor-axis-targeted therapy (ARAT) approved by Health Canada in three clinical disease states of prostate cancer across four indications[ii]

At Astellas we empower our employees and encourage a culture that is achievement oriented and allows everyone to work to their full potential. It is exactly these high-trust and high-performance workplace cultures that are selected by Great Place to Work®, a global authority that recognizes the world's Best Workplaces™. We are very excited to have been named a Best Workplaces™ by the Great Place...

Astellas ranked 27 on the Great Place to Work® Institute's Best Workplaces™ in Canada list, in addition to recognition on the 2020 lists of Best Workplaces™ in Canada for Inclusion and Women MARKHAM, ON, April 16, 2020 – Astellas Pharma Canada, Inc. has been named on the List of Best Workplaces™ by Great Place to Work® for the fifth consecutive year. In addition to being certified as a Great Place...

April 3, 2020 In an effort to help ensure patient safety and alleviate strain on healthcare resources during the COVID-19 pandemic, Astellas is implementing changes to our clinical trial operations. In countries with rapid growth of new COVID-19 cases, Astellas is suspending start-up activities involving study sites for new interventional clinical studies. We are also suspending enrollment of new...

COVID-19 Supply Situation We continue to monitor the global COVID-19 situation. As of March 20, 2020, the supply, manufacturing and distribution of Astellas products for Canada are not impacted and patients will continue to be able to receive all approved medicines, without interruption related to COVID-19. As the COVID-19 situation continues to evolve, Astellas remains focused on protecting our...